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ABSTRACT: This paper aims to examine the rise and the fall of biomedicine in the public 
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peaceful uses of atomic energy. I will argue that despite the major financial investment, the 
development of the uses of radioisotopes and their important impact on biology and clinical 
practices, the assessment of medical uses remained relatively limited. As consequence, the 
place of biomedicine in the public legitimization of financial investment and civilian uses of 
nuclear energy began to decline from the late 1950s.
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1. Introduction
Until the late 1950s, biological and medical applications were presented as 
the most important successes of the peaceful uses of atomic energy. The 
eagerness with which this discourse of promotion was developed almost 
represented a kind of«incantation»which can be interesting to investigate. 
Several scholars proposed the idea of viewing investment in biological and 
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medical questions as a symbolic operation that involved asserting that the 
use of nuclear energy to understand and support life would help conjure 
its deadly potential 1 and an attempt at«redeeming»the act of having 
used the nuclear bomb 2. This desire for redemption made it possible to 
understand the «moral economy» of a part of the scientific community 
after the use of a destructive weapon that it had taken part in developing. 
However, it only realised part of what was at stake in the development of 
the biological and medical applications of the atom, and more generally 
its «peaceful» uses. These applications found a place on the agenda for 
a variety of reasons, strongly interlinked with each other, related to the 
context instigated by World War II and the interests of professional and 
political legitimization. This paper aims to clarify some of these by studying 
the making of atomic biomedicine at a nuclear complex and the stakes 
underlying its development. 
The making of a «biomedical complex» in the atomic age has been 
investigated by many scholars 3, mainly from a history of biology and medicine 
perspective 4. Using these different studies, one can argue that the policy 
 1. Strasser, Bruno. La fabrique d’une nouvelle science: La Biologie Moléculaire à l’Age Atomique 
(1945-1964). Florence: Olschki; 2006.
 2. Lindee, Mary Susan. Suffering made real: American science and the survivors at Hiroshima. 
Chicago: University of Chicago Press; 1994. Rasmussen, Nicolas. The midcentury biophysics 
bubble: Hiroshima and the biological revolution in America, revisited. History of Science. 
1997; 35: 245-293. Creager Angela; Santesmases, María Jesús. Radiobiology in the atomic 
age: Changing research practices and policies in comparative perspective. Journal of the 
History of Biology. 2006; 39: 637-647.
 3. Hewlett, Richard; Anderson, Oscar; Duncan, Francis. A history of the United States Atomic Energy 
Commission. 2 vols., Berkeley: University of California Press; 1990, Beatty, John. Genetics 
in the atomic age: The Atomic Bomb Casualty Commission, 1947-1957. In: Benson, Keith; 
Maienschein, Jane; Rainger, Ronald, eds. The American expansion of biology. New Brunswick: 
Rutgers University Press; 1991, p. 284-324. Rasmussen, n. 2. De Chadarevian, Soraya. Designs 
for life molecular biology after World War II. Cambridge: Cambridge University Press; 2002. 
Strasser, Bruno; de Chadarevian, Soraya, eds. Molecular Biology in post-war Europe. Studies 
in the History and Philosophy of Science. 2002; 33C (special issue). Strasser, n. 1. Gaudillière, 
Jean-Paul. Inventer la biomédecine: la France, l’Amérique et la production des savoirs du 
vivant (1945-1965). Paris: Éditions de la découverte; 2002. Creager, Angela. Nuclear energy 
in the service of biomedicine: The U.S. Atomic Energy Commission’s Radioisotope Program, 
1946–1950. Journal of the History of Biology. 2006; 39: 649–684.
 4. In addition to the history of biomedicine in the nuclear age, another fairly well documented 
aspect is the role of radioisotopes as instruments of foreign policy during the Cold War. See : 
Krige, John. The politics of Phosphorus-32: A cold war fable based on fact. Historical Studies in 
the Physical and Biological Sciences. 2005; 36: 71-91. Krige, John. Atoms for peace, Scientific 
internationalism, and scientific intelligence. Osiris. 2006; 21: 161-181. Creager, n. 3.
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of promoting and financing the biomedical activities, first implemented 
by the American Atomic Energy Commission (AEC), then taken up in 
several European countries responded to a set of three problems. One of 
these was to study the effects of atomic weapons on the population and 
therefore gain better control of atomic tests in the atmosphere or to act for 
civilian defence. The second deals with biologists and physicians’ anxiety to 
benefit from previously unknown resources, for the reinforcement of pre-
war practices, or to construct new disciplinary or institutional ones. The 
third concerns the difficulty of publicly explaining and socially legitimizing 
nuclear energy. I will focus my interest on this third aspect by examining the 
rise and the fall of biomedicine in the public legitimization of investment 
and uses of nuclear energy.
The starting point for this paper is the observation of a shift between 
the central place of biological and medical applications in institutional and 
political discourses and their effective place in the nuclear complex: their 
place in public discourse went so far as to exceed the place they occupied 
in nuclear institutions’ concerns and investments, in comparison with the 
construction and study of reactors, research into physical science or the 
prospecting of uranium. The nuclear programs were expensive. Huge 
amounts of money were used to finance the construction of nuclear 
reactors and weapons. These activities were rather difficult to publicly 
legitimize. One way of doing this was to show the major benefit of a 
reactor’s large-scale production: radioisotopes. Nuclear institutions 
therefore created a veritable «rhetoric space» 5, which maintained the 
promises of application in various fields —health, industry and agriculture. 
The construction of «rhetoric space» did not only mean producing 
discourses. Indeed, in addition to the public promotion of the applications 
of radioisotopes, nuclear institutions, including the first of them, the 
Atomic Energy Commission (AEC), financed the development of such 
applications. The decisions and actions undertaken in the USA were 
generally used as the basis for what was tried in Europe. The American 
policy of the production, distribution and application of radioisotopes 
formed much of the framework for their uses 6. The adoption of this policy 
 5. Van Lente, Haron and Rip Arie. The rise of membrane technology. From rhetorics to social 
reality. Social Studies of Science. 1998; 28 (2): 221-254.
 6. Krige, John. American hegemony and the postwar reconstruction of science in Europe. Cambridge 
MA: The MIT Press; 2006.
Soraya Boudia
Dynamis 20 09; 29: 241-259
244
by European countries and later the International Atomic Energy Agency 
(IAEA), reinforced and amplified the biomedical practices associated to 
radioisotopes. The case of France is an interesting illustration of how this 
policy was taken up and readapted to the conditions of the country and 
its institutional stakes.
Financial investment and the collaborations involved finally managed 
to generate a social reality for the medical applications of radioisotopes. 
First, I would like to describe how this field of research and its applications 
materialized. In doing so, if it is heuristic to think of biomedicine as an 
ensemble that integrates both biological and clinical research, then in order 
to understand the range of practices and to evaluate what the applications 
of radioisotopes were, it is essential to make a distinction between biology 
and medicine. Indeed, radioisotopes proved to be an instrument of primary 
importance in investigations of living things and became a traditional tool 
for use in biomedical laboratories. I would like to show that in therapy, the 
situation was somewhat different. Their employment only became possible 
after nuclear institutions adopted a voluntarist policy that made them 
available at low cost, financed work for their applications and especially 
engaged in a policy of systematically replacing radium in the therapeutic 
niches, mainly cancer therapy, where these radioisotopes could be used. 
Secondly, I will argue that despite the major financial investment, the 
development of the uses of radioisotopes and their important impact on 
biology and clinical practices, the assessment of medical uses remained 
relatively limited. In consequence, the place of biomedicine in the public 
legitimization of financial investment and civilian uses of nuclear energy 
began to decline from the late 1950s.
2. From radium to radio-isotopes: The construction of an «atomic 
medicine»
At the beginning of the 1950s, fundamental and applied research into 
«atomic biology and medicine», financed by nuclear institutions, expanded 
rapidly. In medicine, the place of radioisotopes was built up around their 
internal and external use in diagnosis, on the one hand and, on the other, 
in therapy. In diagnosis, the first work was undertaken in the period 
before the war, and was centred on the functional exploration of organs, 
through the tracer method, which had been devised by Georg Von Hevesy 
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in 1923 and gradually proved to be a powerful tool for the investigation 
of living metabolism 7. The discovery of artificial radioactivity by Irene 
and Frederic Joliot in 1934 in Paris, followed by the production of radio-
isotopes with accelerators at Ernest Lawrence’s laboratory in Berkeley 
widened the range of mobilizable radioisotopes in such investigations. 
This led to the development of studies of the diagnosis and treatment of 
thyroid metabolism and diseases 8. Encouraged by this early success, their 
other work sought to widen the range of explored organs and to improve 
the techniques for doing so 9. Along with the functional exploration of 
organs, a second matter was studied: that of medical imaging. In the early 
1950s, the replacement of the Geiger-Müller counter with scintigraphy 
techniques, initiated by the American Ben Cassen, paved the way for the 
installation of a new instrumentation that made it possible to transform 
the radiation curves emitted by radioisotopes in the body into images. The 
development of a scintillations camera by Harold Anger at the UCLA, an 
exploration apparatus, was a significant development 10, as it became the 
apparatus par excellence for nuclear medicine services.
Symbolically, it was in therapy that the promoters of nuclear energy 
sought to obtain results. The capacity of certain radioisotopes to be 
concentrated in human tissue gave hope for new therapeutic applications. 
Contrary to diagnosis, in which the use of radio-isotopes was seen as an 
 7. Kevles, Daniel; Geison, Gerald. The experimental life sciences in the twentieth century. Osiris. 
1995; 10: 97–121, 233–241. Creager, Angela. The industrialization of radioisotopes by the 
U.S. Atomic Energy Commission. In: Grandin, Karl; Wormbs, Nina; Widmalm, Sven, eds. The 
science-industry nexus: History, policy, implications. Sagamore Beach. MA: Science History 
Publications; 2004, p. 143-167. Kohler, Robert; Schoenheimer, Rudolph. Isotopic tracers and 
Biochemistry in the 1930s. Historical Studies in Physical and Biological Sciences. 1977; 8: 
257-298. Creager, Angela. Tracing the politics of changing postwar research practices: The 
export of «American» radioisotopes to European biologists. Studies in History and Philosophy 
of the Biological and Biomedical Sciences. 2002; 33C: 367-388.
 8. Sawin, Clark; Becker, David. Radioiodine and the treatment of hyperthyroidism: the early history. 
Thyroid. 1997; 7: 163-176. On the French situation, see Fragu, Philippe. How the field of thyroid 
endocrinology developed in France after World War II. Bulletin of the History of Medicine. 2003; 
77 (2): 393-414. On Spain see: Santesmases, María Jesús. Peace propaganda and biomedical 
experimentation: Influential uses of radioisotopes in Endocrinology and Molecular Genetics 
in Spain (1947–1971). Journal of the History of Biology. 2006; 39: 765-794.
 9. Tubiana, Maurice. Les isotopes radioactifs en biologie et en médecine. Paris: Masson; 1950.
 10. Blahd, William; Bauer, Franz; Cassen, Benedict. The practice of Nuclear Medicine. Springfield 
III: CC Thomas; 1958. Rheinberger, Hans-Jörg. Putting isotopes to work: Liquid scintillation 
counters, 1950-1970. In: Joerges, Bernward; Shinn, Terry, eds. Instrumentation: Between 
science, state and industry. Dordrecht: Kluwer Academic Publishers; 2001, p. 143-174.
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innovation, radioelements were widely used in therapy 11. At the turn of 
the 20th-century, the use of radium in medicine (such as in x-rays) led 
to expansion in the use of physical agents in medicine: electrotherapy, 
hydrotherapy and mechanotherapy, among others. The deployment of 
radium as a «therapeutic agent», and the extension of its uses from physics 
to medicine was anything but automatic; it was largely related to the 
activity of the manufacturers of radioactive elements 12. To create a market 
for radium, these industrialists developed a plethora of actions intended 
for the medical world: the cost-free availability of radium sources, the 
financing of biological research laboratories and the marketing of the various 
apparatuses intended to facilitate its employment. Radium was therefore 
a non-specific therapeutic agent in the sense that it was used for a broad 
range of pathologies: in dermatology-syphiligraphy and gynaecology, as 
well as for certain nervous afflictions and rheumatology.
In the interwar period, centers specialized in the treatment of cancer 
were created in several countries. In these centers, besides surgery, there 
were major strides forward in one particular technique: radiotherapy. 
The term ‘radiotherapy’ was used from the First World War to indicate 
the ensemble of methods of radiation treatment. Radium was used in 
accordance with two techniques. The first, curietherapy (a denomination 
that replaced «radiumtherapy» in 1919) generally indicated therapy using 
radioactive elements that consisted of introducing radium tubes into 
natural cavities or bringing them into contact with lesions. The second 
method, telecurietherapy, was developed in the late 1920s due to the 
growth of the radium industry. An increasing quantity of radium, about 
a few grams, was placed in increasingly imposing apparatuses 13. These 
 11. Vincent, Bénédicte. Naissance et développement de la pratique thérapeutique du radium en 
France, 1901-1914 [PhD thesis]. Paris 7 University; 2002. Mould, Richard. A history of X-Rays 
and radium with a chapter on radiation units, 1895-1937. Surrey: IPC Building & Contracts 
Journals Ltd; 1980. Hayter, Charles. An element of hope: Radium and the response to cancer 
in Canada, 1900–1940. Montreal/Kingston: McGill-Queens University Press; 2005. On history 
of cancer in the US, see: Patterson, James T. The dread disease: Cancer and modern American 
culture. Cambridge MA: Harvard University Press; 1987. On France: Pinell, Patrice. Naissance 
d’un fléau: histoire de la lutte contre le cancer en France (1890-1940). Paris: Editions Métaillié; 
1992.
 12. Vincent, n. 11.
 13. Cottenot, Paul; Laborde, Simone. Radiothérapie. Rayons X. Radium. Paris: Éditions Médicales 
Norbert Maloine; 1934. Bordry, Monique; Boudia, Soraya, eds. Les rayons de la vie, une histoire 
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apparatuses, sometimes called «radium bombs», were useful in external 
treatment of cancer with gamma rays of radium.
In the post-war period, when nuclear institutions were seeking to 
promote therapeutic research for radioisotopes, they «naturally» made 
the treatment of cancers their predilection. Angela Creager showed that, 
in its desire to promote the use of radioisotopes in therapy, from April 
1948 onwards, the AEC decided to place radiosodium, radiophosphorus, 
and radioiodine at free disposal for use in cancer research, diagnosis, or 
therapy. This exemption from payment was extended to all radioisotopes 
at the beginning of 1949 14. This provision policy was reinforced by the 
construction of clinical cancer research hospitals at Argonne and Oak 
Ridge. However, as one of the promoters of radioisotopes pointed out in 
the 1950s: «Until now the most important use of radioisotopes has been to 
replace traditional means of radiotherapy» 15. Indeed, the increasing mass 
of radioisotopes was only able to completely integrate into medicine when 
radium was replaced. After the installation of the medical division at Oak 
Ridge in spring 1949, researchers examined the most promising isotopes as 
potential externally administered radiation sources. Feasibility studies were 
undertaken in parallel in Canada by Jones and Smith and in the USA by 
Grimmet and Fletcher. Cobalt 60 was the first radioisotope to be promoted 
as a replacement for radium. In 1951, the radioisotope service at Chalk River 
in Canada manufactured, for experimental and clinical reasons, two sources 
of Cobalt 60 of 1,000 curies each, i.e. a hundred times more powerful than 
the sources of radium used before in telecurietherapy 16. By increasing the 
power of the sources, the idea was to shorten treatment times. In August 
1951, an item of telecobaltotherapy apparatus was installed in the hospital 
at the University of Saskatchewan in Saskatoon, and the second source 
was used in another system installed in the Victoria Hospital, London 
(Ontario). At Oak Ridge, the Medical Division also worked on the design 
of a piece of telecobaltotherapy apparatus in collaboration with the General 
des applications médicales des rayons X et de la radioactivité en France. Paris: Institut Curie; 
1998.
 14. The program was modified in 1952, for radioisotopes used in the treatment, diagnosis, and 
study of cancer, users had to pay 20% of production costs. Creager, 2002, n. 7.
 15. Veall, W. Quelques applications chimiques et thérapeutiques des isotopes radioactifs. Atomes. 
1955; 108: 77-80 (80).
 16. IAEA. Emploi en radiotéléthérapie des radioisotopes et des appareils à haute énergie. Situation 
actuelle et recommandations. Vienne: IAEA; 1960.
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Electric Company, which was responsible for building the apparatus. In 
September 1953, the first system was installed at the M. D. Anderson 
Hospital, Houston (Texas). Another radioisotope was studied for its use in 
radiotherapy: Cesium 137 17. It was at Oak Ridge that the first Cesium 137 
teletherapy apparatus was developed in January 1955 18. A second system 
of the same power was installed at the Royal Marsden Hospital, London in 
October 1956. Three years later, according to data collected by the IAEA, 
there were about 700 cobaltotherapy systems in 44 countries, including 
264 in the USA, 40 in France and 33 in Great Britain 19. 
The extension of the therapeutic uses of radioisotopes by the replacement 
of radium in teletherapy and curietherapy was impelled and supported 
by a voluntary policy which did not find its justification in better or new 
results but in the low cost of radioisotopes. Simone Laborde, one of the 
pioneers of curietherapy and telecurietherapy noted in 1953 in an article 
in Science et Vie, one of the most popular popularization magazines in 
France: «the use of Cobalt 60 does not offer new scientific interest and its 
use depends only on practical factors: its price being much lower than that 
of radium» 20. Six years later, an expert group convened by the IAEA to 
assess radioteletherapy radioisotopes wrote in its report: «There can be no 
doubt that the fast development of telecobaltotherapy is explained mainly 
by its simplicity and its advantageous price» 21. This low cost was brought 
about by the policy of nuclear power institutions. To promote their use, 
they took responsibility for a part of the expenses of their production and 
preparation. They promised to deliver them «without profit, at a price far 
from high, barely representing even the handling expenses» as Bertrand 
Goldschmidt, one of the promoters of this policy in France, put it 22. This 
choice was initiated by the AEC which did not charge for the production 
 17. Amalric, Robert; Vigne, Jacques-Paul. Le Césium 137 en téléthérapie. Paris: Gauthier-Villars et 
Cie; 1962.
 18. Brucer, Marshall. Special report of medical division on teletherapy design problems, I Cesium 
137. Oak Ridge Institute of nuclear studies, Report TID 5086 (second revision); 1955. Brucer, 
Marshall. The industrial Atom-Teletherapy devices with radioactive isotopes. Technical 
information Service, report TID 8007; 1956. Comas, Frank; Brucer, Marshall. First impressions 
of therapy with Cesium 137. Radiology. 1957; 69: 231-235.
 19. IAEA, n.16.
 20. IAEA, n.16.
 21. IAEA, n.16, p. 34.
 22. Goldschmidt, Bertrand. L’aventure atomique- ses aspects politiques et techniques. Paris: Fayard; 
1962.
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expenses of their radioisotopes, but sold them at only 60% of their cost. 
The calculation of this figure is actually a difficult operation, insofar as it 
should include a share of the costs of the construction and maintenance 
of the reactors. 
Due to this policy of radium replacement, the very cheap provision of 
radioisotopes and the financing of fundamental and therapeutic research, 
nuclear institutions succeeded in durably installing radioisotopes in 
therapy.
3. Biomedicine and radioisotopes in France
In France, just as in the United States, the leader in the production and 
distribution of radioisotopes was the organization in charge of nuclear 
programs, the Commissariat à l’énergie atomique (CEA). This institution, 
created by order on October 18, 1945, had the role of continuing «scientific 
and technical research for the use of industry and national defense» 23. At its 
head was one of the great international figures of nuclear science, Frederic 
Joliot-Curie 24. Winner of the Nobel Prize for Chemistry in 1935, along with 
his wife Irene Joliot-Curie, for the discovery of artificial radioactivity, Joliot 
was regarded to be the leader of a French scientific community anxious 
to give a new impetus to French nuclear research. He became involved in 
the construction of the CEA, surrounded by a close team out of which Lev 
Kowalski and Hans Halban emerged, who had worked in Canada during the 
Second World War, and Bertrand Goldschmidt, the only Frenchman to have 
been briefly admitted onto the Manhattan project. Their main project was 
the construction of an atomic pile. However, biological issues very quickly 
found a place in their concerns. Joliot had a very real interest in working 
in biology. From 1935 onwards, in financing research for the construction 
of a cyclotron at the College of France, where he managed a laboratory, 
radioisotope applications in biology and medicine were proposed. With 
Antoine Lacassagne at the chair of experimental radiobiology at the College 
of France, he carried out work from 1941 onwards on rabbit cancers caused 
 23. Weart, Spencer R. Scientists in power. Cambridge, Mass.: Harvard University Press; 1979. 
Hecht, Gabrielle. The radiance of France. nuclear power and national identity after World 
War II. Cambridge MA: MIT Press; 1998. 
 24. Pinault, Michel. Frédéric Joliot-Curie. Paris: Odile Jacob; 2000.
Soraya Boudia
Dynamis 20 09; 29: 241-259
250
by the irradiation of neutrons 25. Collaborations were also started up in the 
endocrinology laboratory that Robert Courrier directed 26. In 1944, Joliot, 
Pierre Sue, a radiochemist and sub-manager of Joliot’s laboratory, Courrier 
and one of his collaborators, Alain Horeau, carried out the first synthesis of 
a thyroxin hormone marked by radioactive iodine. When Joliot was working 
on the foundation and direction of the CEA, it was almost «natural» for 
him to ask, in late 1946, Lacassagne and Courrier to join the scientific 
committee of the CEA and deal with biomedical questions. One of this 
committee’s concerns was the implementation of American requirements 
that accompanied the marketing of radioisotopes by the AEC. Joliot asked 
Lacassagne and Courrier to organize a biology and medicine service within 
the CEA, in charge of channelling doctors’ requests and proposing a regulation 
project on the distribution of radioactive products. The policy of control, put 
in place by the AEC for the delivery of radioisotopes, far from representing 
a constraint for the CEA, was to be used as a springboard to assert its own 
control on the circulation and uses of radioisotopes in France.
The CEA and Joliot’s laboratories were not the only places where interest 
in radioisotopes was being shown. Somewhere else would go on to occupy 
an increasing amount of space in the landscape of the use of radiation in 
biology and medicine. This was the National Institute of Hygiene (INH). This 
Institute was created by initiative of the Vichy government with the support 
of the Rockefeller Foundation, by a law of November 30, 1941. Louis Bugnard 
was put in charge of it in 1946. Trained as an engineer and a physician at 
the same time, he was a specialist in radiotherapy and a professor of medical 
physics at the University of Toulouse. As Gaudillière showed, Bugnard played 
an active role in the movement of the «modernization of health» in France, 
the use of radioisotopes being then one of the most important components 
of this project. Bugnard’s sustained interest in radioisotopes was born out 
of a four-month trip he took to the United States from 1945-1946 27. At 
the head of the INH, he set up a grant-system to train young doctors in 
research with radioisotopes, by sending them to the United States. He also 
obtained funds for the acquisition of radioisotopes, in particular at the 
 25. Chamak, Brigitte. Un scientifique pendant l’occupation: le cas d’Antoine Lacassagne. Revue 
d’Histoire des Sciences. 2004; 57: 101-133.
 26. Fragu, Philippe. How the field of thyroid endocrinology developed in France after World War 
II. Bulletin of the History of Medicine. 2003; 77 (2): 393-414. 
 27. Gaudillière, n. 3. 
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Natural Sciences Division of the Rockefeller Foundation. At Rockefeller, 
he did not hesitate to point out the fact that in France a monopoly on 
radioisotopes was being exerted by Joliot, Lacassagne and Courrier 28.
The end of 1948 saw the first step in the French nuclear program: the 
setting up of a pile called Zoe that was intended for the study of chain 
reactions, neutron physics and the production of radioisotopes. From 1949 
onwards, the CEA started to provide radioisotopes intended for public 
use. So, a double policy was coming into play: on the one hand national 
control of an administrative nature and on the other hand a promotion 
of the use of radioisotopes by financing research into their uses. In 1949, 
a decree established an inter-ministerial commission on the purchase of 
artificial radioelements abroad, the principal concern being the verification 
of the conditions imposed by the United States for the export of its 
radioisotopes. Requests emanating from people or institutions in France 
were subject to approval either from the Ministry of Health via the INH if 
they were intended for research into human biology or medicine, or from 
the Ministry of National Education (CNRS), for radioisotopes intended 
for research into physics, chemistry, and animal and vegetable biology. 
The representatives of the CEA were the only ones to rule on all requests, 
whatever their origin.
The use of radioisotopes was thus managed jointly by the CEA, the INH 
and CNRS throughout the 1950s. After Joliot-Curie’s revocation from the 
CEA in 1950 because of his communist links, the institution saw important 
changes with the progressive arrival of new figures. Concerning biology 
and medicine, Lacassagne, whose stance against atomic testing was public 
knowledge, did not have his membership of the scientific committee renewed. 
From 1951 onwards, Bugnard, named as a member of this committee, saw 
the influence of his group widen with the arrival of young people trained in 
particular in the USA. From 1953 onwards, the French field of radioisotopes 
saw several changes. Up until this date, the CEA’s orientation had been 
primarily scientific; in 1952 a decision was made for the French nuclear 
program to be industrialized and militarized. This same year, a second 
reactor, more powerful than Zoe, came into operation, bringing about an 
 28. Gaudillière, Jean-Paul. Normal pathways: Controlling Isotopes and building biomedical research 
in postwar France. Journal of the History of Biology. 2006; 39: 737-764. Kraft, Alison. Between 
medicine and industry: Medical Physics and the rise of the radioisotope 1945-65. Contemporary 
British History. 2006; 20: 1-35.
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increase in the quantities of radioisotopes available. In parallel, more explicit 
provisions were adopted on the circulation and use of these radioisotopes. 
A new inter-ministerial commission, replacing the preceding one, was from 
now on in charge of formulating opinions and proposals on all questions 
of a general nature that were raised by the development and application of 
regulations relating to radioelements 29. It brought together representatives 
of different ministries: Bugnard at the IHN, one representative from the 
CNRS and two from the CEA. Bertrand Goldschmidt, the CEA’s director 
of international relations, was the vice-president and Charles Fisher, in 
charge of the CEA’s Department of Radioisotopes, was the secretary of 
the committee. So the CEA played a determining role. Moreover, it was 
the only organization that did not face checks on the import and export of 
radioisotopes. Along with the control policy, the use of radioisotopes was 
promoted. A twice-yearly course was set up in 1950 by the CEA, the INH 
and CNRS. In addition to this, subsidies, initially from the INH, the CNRS 
and the National Social Security Office were granted to several laboratories 
and hospital services in order to acquire the necessary material for the use 
of radioisotopes 30.
Biology and medicine’s place was nevertheless still limited within the 
CEA. It was only in 1953 that a biology department was set up. Two objectives 
presided over the installation and structuring of this department: the use of 
radioisotopes and the study of the biological effects of radiation 31. A young 
«protégé» of Bugnard’s, Jean Coursaget, was named head of department. The 
CEA also created an «advisory commission on biological research» whose 
purpose was to help it to define its policy. Several important specialists of 
institutional importance in the fields of biology and medicine in association 
with radiation were invited. Its presidency was entrusted to Courrier, who 
had also become the permanent secretary of the Academy of Sciences, and 
the vice-president was Bugnard, the directed the INH and the «experimental 
medicine» section of the CNRS. The director of the Institute Pasteur, 
 29. Bugnard, Louis; Vergne, Jacques. Réglementation de l’utilisation des radio-isotopes en France. 
August 1955. Archives of CEA. Fontenay aux Roses. CEA Report n°438. Technical reports.
 30. Coursaget, Jean. Utilisation des radioéléments en France dans le domaine de la médecine et 
de la biologie. Saclay: Centre d’études nucléaires, Service de documentation; 1955. For a 
study of one French radioisotopes site, see the study of Gaudillière on The Hospital Necker, 
Gaudillière, n. 28.
 31. Commissariat à l’énergie Atomique. Programme 1954 – biologie. Archives of CEA. Fontenay 
aux Roses. F4.20.22.
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Jacques Tréfouël, and the person in charge of research in the Army’s health 
service were also members. This commission met several times a year and 
its principal activity was to choose which of the research projects on and 
with radioisotopes that had been suggested by French laboratories should 
be financed by the CEA 32. This production and promotion led to an 
increase in the number of radioisotope consumers in France. There were 
6 in 1949, 33 in 1950, 45 in 1951, 49 in 1952, 59 in 1953, 104 in 1954 33, 
 32. Lacassagne Papers, Fonds. Relations avec des organismes de recherche nationaux. Archives of 
Pasteur Institut. Paris. CEA LAC. Org.1-12, Org6.
 33. Fisher, Charles. Statistiques sur la production et l’emploi des radio-éléments artificiels en France. 
Paris: Commissariat à l’énergie Atomique; 1955.
Graph. 1. Isotopes deliveries in France (1949-1961)
Source: Reproduced from Commissariat à l’énergie 
Atomique. Rapports. 1961. Archives of CEA. Fontenay 
aux Roses.
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981 in 1960 and 1,171 in 1961 34. If, in the first years, radioisotopes had 
initially been partly imported, primarily from Great Britain, by 1960, the 
CEA was able to satisfy 90% of the French requirements for radioisotopes 
and exported 30% of its production 35. Just as in the American case, biologists 
and doctors represented a significant number of consumers, using 2/3 of 
the quantity of radioisotopes produced by CEA reactors 36. However, this 
extension should not disguise the fact that throughout the 1950s and 1960s, 
biology and medicine remained marginal spheres of activity within nuclear 
institutions, the construction of reactors and nuclear plants being the true 
heart of their activity.
French production is clearly lower than American production. Between 
1946 and 1955, the AEC made 64,000 shipments of radioactive materials 
available to laboratories, industries and clinics 37.
4. Biomedicine and the construction of the social acceptability of 
nuclear energy
The policy of the promotion of peaceful nuclear energy applications quickly 
expanded with the launch of the American operation Atoms for Peace 38. 
Several biologists and physicians working with nuclear organizations 
resumed, through conviction or for strategic reasons, the mission that 
President Eisenhower, in his famous speech, had assigned to them at the 
United Nations: to apply atomic energy to the needs of agriculture, medicine, 
and other peaceful activities. The result was the creation or development of 
departments of biology within nuclear institutions, the financing of whole 
sectors of biological and medical research, as well as the installation of 
clinical structures using radioisotopes.
However, despite much effort, the assessment of medical uses remained 
relatively limited in comparison to the promises, expectations and investments 
 34. Commissariat à l’énergie Atomique. Rapports. 1961. Archives of CEA. Fontenay aux Roses.
 35. CEA Commissariat à l’énergie atomique. Paris: Département des relations extérieures du C.E.A; 
1960.
 36. In the US, ¾ of radioisotope production was used in biomedicine. Creager, 2004, n. 7.
 37. CEA, n. 34.
 38. Weart, Spencer. Nuclear fear: a history of images. Cambridge MA., London: Harvard University 
Press; 1988. Hewlett, Richard G.; Holl, Jack M. Atoms for peace and war, 1953-1961: Eisenhower 
and the Atomic Energy Commission. Berkeley: University of California Press; 1989.
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made. From the very start of the 1950s, Maurice Tubiana, a key French actor 
in the biology and medicine of radioisotopes declared that: «concerning 
the immense services rendered by artificial radioelements in physiological 
and metabolic studies, their clinical applications, in the functional and 
diagnostic exploration of the patient, seem relatively poor» 39. A few years 
later, Lacassagne, one of the international specialists in the treatment of 
cancers made a similar report: «at present, the results for the use of nuclear 
energy in the therapy of cancers are still of little importance» 40. In its report 
at the Geneva conference on the peaceful applications of nuclear energy in 
1955, one of the most important French popularization journals, Atomes, 
estimated that «in biology and medicine few new results or treatments have 
been announced» 41. At the third Geneva conference, a group of experts 
from the IAEA and the World Health Organization (WHO) reported that 
in ten years, the projections in the uses of radioisotopes in diagnosis and 
therapy suggested an increase in the power of the sources of cobalt, a 
simplification and standardization of the techniques, increased reliability of 
isotopically labelled materials and counting equipment, and the subjection 
of a wider variety of organs and conditions to scrutiny by isotopic methods. 
The conclusion was that «further refinement of applications without the 
development of startlingly new ones» was required 42. From the start of the 
1960s, certain leaders of nuclear programs made a lucid assessment of the 
medical applications of radioisotopes: «the great hopes that had become 
quickly widespread in the public on the therapeutic use of radioisotopes 
for cancer have been partly disappointed» 43. 
The limits of the therapeutic prospects for radioisotopes were seldom 
publicly discussed but several signs indicated the possibility of subtle changes. 
In the mid 1950s, the AEC commission’s budget for biomedical research was 
about 25 million a year. 37% of this was spent on research into the effects 
of radiation, mainly to understand risks of radiation, while the «beneficial 
 39. Tubiana, n. 9, p. 237.
 40. Lacassagne, Antoine. L’emploi des radioéléments en médecine. Industries atomiques. 1956; 2: 
3-5.
 41. La conférence internationale sur l’utilisation de l’énergie atomique à des fins pacifiques. Atomes. 
1955; 115: 327-328 (328).
 42. Belcher, E. H. et al. Advanced in the use of isotopes and radiation sources in medicine. Proceedings 
of the 3rd International Conference on the peaceful uses of atomic energy. United Nations, 
vol. 15; 1965, p. 275-284 (278).
 43. Goldschmidt, n. 22, p. 231.
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effects of radiation» accounted for 34%, and 21% was devoted to studies of 
industrial health and safety 44. These figures indicated that studies of the 
biological effects of radiation —hazards and protection— outdid those on the 
biological and therapeutic applications of radioisotopes. This change was due 
to the development of public controversy surrounding the effects of fallout. 
From the early 1950s, with the nuclear arms race and the multiplication 
of atomic tests in the atmosphere, an intermingling of scientific and social 
controversies developed on the consequences of radiation 45. Apart from 
the threat of nuclear destruction, which worried many people during the 
Cold War years, a series of other problems arose: the direct and indirect 
effects of radiation, potential contamination of the soil and water and its 
consequences on animals and plants, and therefore food, or the genetic 
effects of radiation and climate change. 
The debates on the effects of radioactive fallout were initially limited 
to specialist circles, but took on an increasingly more important public role 
after the accidental contamination of Japanese fishermen by an American 
test in 1954 46. Genetic effects —changes induced by radiation and its 
consequences— emerged as one of the central subjects of these controversies. 
They particularly caught the attention of the various protagonists because 
they had both an immediate effect, and also an effect that would last for 
several generations. Because of this, there was an irreversible deterioration 
 44. Hewlett; Holl, n. 38.
 45. Boyer, Paul. By the bomb’s early light: American thought and culture at the dawn of the atomic 
age. Chapel Hill: The University of North Carolina Press; 1994. Hacker, Barton. Elements of 
controversy: the Atomic Energy Commission and radiation safety in nuclear weapons testing, 
1947-1974. Berkeley: University of California Press; 1994. On the history of public mobilization 
against the nuclear bomb, see: Wittner, Lawrence. The struggle against the bomb. One world 
or none: A history of the world nuclear disarmament movement through 1953. Stanford: 
Stanford University Press; 1993. Wittner, Lawrence. The struggle against the bomb. Resisting 
the Bomb: a History of the World Nuclear Disarmament Movement, 1954-1970. Stanford: 
Stanford University Pres; 1997. Kopp, Carolyn. The origins of the American scientific debate 
over fallout hazards. Social Studies of Science. 1979; 9 (4): 403-422.
 46. On March 1, 1954, the displacement of the radioactive cloud generated by an H-bomb test, 700 
times more powerful than that of Hiroshima, led to the contamination of several thousand 
square kilometers of territory, and effected several Japanese fishermen who were 160 km 
from the testing ground, i.e. outside the safety-zone. The event led to strong reactions and 
clearly showed that despite the words of the promoters of atomic tests, they were far from 
controlling all parameters. The position of the AEC played a major role in the amplification 
and promotion of such controversies. While seeking to minimize, indeed even to deny the 
dangers incurred, the AEC pushed a certain number of American scientists to publicly voice 
their dissention.
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of human-beings, which drove people’s imaginations towards images of the 
decay of the species and the potential for the production of monsters. The 
risk of radiation cancers was also a broad subject of research and debate. 
Attention was particularly focused on leukaemia caused by dissemination 
into the environment of radioisotopes resulting from nuclear explosions, in 
particular Strontium 90 and Cesium 137. In these controversies, radiation 
specialists played a slightly ambivalent role. In many cases, they were the 
very cause of these controversies, which they expressed publicly, in turn 
giving voice to concerns or latent distrust in other areas. These same 
specialists, or at least some of them, were also those to whom the decision-
makers turned to for help to put an end to the controversies. Between 1955 
and 1958, following the development of various controversies, there was a 
«flowering» of committees of national and international experts that were 
all working in inter-connection. The same governments that had performed 
the most tests in the atmosphere were those that contributed to the creation 
of commissions whose role was to gauge the degree of danger and to seek 
the means to remedy it. Expertise and regulation activity also developed 
on an international scale with several expert committees being set up to 
study the effects of radiation and work out standards to ensure that it was 
used safely. Specialist physicians in medical physics or radiation were largely 
present in commissions, such as those established by the World Health 
Organization and the United Nations (UN) or in national frameworks such 
as the committee of the American Academy of Sciences and the committee 
of the Medical Research Council (MRC) 47. 
Public controversies on fallout opened windows of opportunity for 
certain groups of researchers who, seizing on the question of the study 
of the effects of radioactivity and the mechanisms of contamination, 
were able to drain finances. Whole fields of research, whose objects of 
study were the mechanisms of health and environment contamination by 
radioactivity experienced unprecedented development, such as the cases 
of radiobiology looking into the mechanisms of the biological effects of 
radiation, or genetic studies that were closely related to the question of the 
effects of radiation. On the environmental level, the first major studies 
of the impact of pollutants on the environment and the consequences 
 47. Boudia, Soraya. Global regulation: Controlling and accepting radioactivity risks. History and 
Technology. 2007; 23 (4): 389-406.
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on human health were produced 48. Because it was possible to follow 
radioactivity through the atmosphere, the oceans, the soil and food chains, 
radioisotopes resulting from exploded bombs were the first pollutants to be 
taken into account on a global scale. Fields of research that are indirectly 
related to the study of nuclear risks, such as oceanography 49, climatology 
or Earth sciences 50 benefited from this movement and in particular from 
the finances it generated. 
5. Conclusion
The making of the «atomic-biomedical complex» was the result of a 
convergence of interests involving several stakes, and was a highly successful 
policy. For a part of the community of biologists and physicians, it made 
it possible for them to find a place in the nuclear complex and to be given 
important resources to develop their activity. For nuclear institutions, it 
offered a market for the use of the radioisotopes that were mass-produced 
by reactors and a justification of the social utility of the colossal investments 
in the building of nuclear technologies. In a way, biomedicine’s place 
and effective contribution was, above all, political. «Political» should be 
understood to have different meanings: the demilitarization of the image of 
the atom, the construction of the neutrality of technologies, or a response 
to the controversies surrounding the effects of radioactive fallout. With 
these different contributions, biomedicine played a role in the installation 
of nuclear technologies. This installation was an irreversible reality due 
to the extent of the investment and the collaboration networks, as well 
 48. Beatty, John. Ecology and evolutionary biology in the war and postwar years: Questions and 
comments. Journal of the History of Biology. 1988; 21: 245-263. Bruno, Laura A. The bequest 
of the nuclear battlefield: Science, nature, and the atom during the first decade of the Cold 
War. Historical Studies in the Physical and Biological Sciences. 2003; 33 (2): 237-260.
 49. Rainger, Ronald. A wonderful oceanographic tool: The atomic bomb, radioactivity and the 
development of American oceanography. In: Rozwadowski, Helen M.; Van Keuren, David K., 
eds. The machine in Neptune’s garden: Historical perspectives on technology and the marine 
environment. Sagamore Beach: Science History Publications; 2004, p. 93–131. Hamblin, Jacob 
Darwin. Oceanographers and the Cold War: Disciples of marine science. Seattle: University 
of Washington Press; 2005.
 50. Doel, Ronald E. Constituting the postwar earth sciences: The military’s influence on the 
environmental sciences in the USA after 1945. Social Studies of Science. 2003; 33 (5): 635-
666.
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as the construction of its social acceptability, which made it possible for 
atomic energy not only to be «a scientific novelty but a economic world 
reality» 51. Stressing the political contribution of biomedicine does not mean 
denying that effective and important scientific results occurred. Research 
and clinical practices in biomedicine were deeply affected and changed by 
nuclear energy and the major investments that were made helped improve 
the diagnosis and therapy of cancers. 
From the early 1960s, because of the weakness of innovation, biomedicine’s 
place in the public legitimization of nuclear technologies began to decline. 
The argument of energy production that had been developing since 1945 
became, along with nuclear power, the dominant argument for the following 
decades, reinforced by the oil crisis of the early 1970s. This movement to 
renew the social and political justifications of nuclear power has since 
continued with, for example, of the contemporary concerns regarding the 
Greenhouse Effect. This reminds us that although nuclear technologies 
have become a massive reality, they are nonetheless just as consistently 
questioned.
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